spironolactone/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on urinary bladder cancer incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“There was no statistically significant association between spironolactone use and risk of ovarian cancer (RR, 1.52; 95% CI, 0.84-2.20; certainty of evidence very low), bladder cancer (RR, 0.89; 95% CI, 0.71-1.07; certainty of evidence very low), kidney cancer (RR, 0.96; 95% CI, 0.85-1.07; certainty of evidence low), gastric cancer (RR, 1.02; 95% CI, 0.80-1.24; certainty of evidence low), or esophageal cancer (RR, 1.09; 95% CI, 0.91-1.27; certainty of evidence low).”
Quoted verbatim from Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.. - Study
- meta-analysis
- Population
- Men and women aged 18 years and older ever exposed to spironolactone, pooled from seven observational studies
Effect 0.89 risk ratio, 95% CI 0.71 to 1.07
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.2022PMID:35138351Permalink
Keep reading
- Everything the graph holds on spironolactone
- Every compound studied against Urinary bladder cancer incidence
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45C8SW2QGGMZEG6AYV7000S